Panelists discuss how riociguat targets the nitric oxide pathway and is approved for both Group 1 PAH and Group 4 chronic ...

Merck said that a phase-three study of its pulmonary arterial hypertension treatment met its primary endpoints.

Shares of Insmed jumped Tuesday after the biopharmaceutical firm reported positive results from a Phase 2 trial for its ...

With patient enrollment now complete, topline results are expected early next year from a Phase 3 trial testing PAH treatment ...

Among patients with pulmonary arterial hypertension, once-daily treprostinil palmitil inhalation powder for 16 weeks reduced ...

In PAH, pulmonary rehabilitation referral and participation rates are low and are significantly affected by demographic and socioeconomic factors.

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced the conclusion of enrollment of the phase 3 ADVANCE OUTCOMES study evaluating the use of an extended-release ...

Merck’s phase 3 HYPERION study of Winrevair meets primary endpoint in recently diagnosed adults with pulmonary arterial hypertension: Rahway, New Jersey Tuesday, June 24, 2025, ...

Gradient Denervation Technologies, a company that makes an ultrasound device for PH, will join an FDA program to speed device ...

Pulmonary hypertension is classified by the World Health Organization according to its causes or associated underlying conditions: Group 1: Pulmonary arterial hypertension (PAH) refers to increased ...

BMPER attenuated PI3K/AKT signaling and suppressed BMP4-driven smooth muscle activation in models of PAH. BMPER overexpression mitigated the vascular remodeling that characterizes pulmonary arterial ...

Insmed Incorporated (NASDAQ:INSM) on Tuesday released topline results from its Phase 2b study of treprostinil palmitil inhalation powder (TPIP), administered once daily in patients with pulmonary ...